ArticleBMC neurology2026
Congenital myasthenic syndromes in a Southeast Asian adult neurology clinic: a long road to diagnosis and therapy.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCongenital myasthenic syndromes (CMS) are rare genetic disorders caused by pathogenic variants in proteins expressed at the neuromuscular junction. Current literature surrounding adult CMS patients remains limited, primarily derived from Western cohorts.
methodsWe present a Southeast Asian cohort of adult patients with a clinical diagnosis of CMS who were evaluated at a tertiary neuromuscular referral center. Patients with seronegative myasthenic syndrome who did not respond to immunotherapy were suspected of having CMS and underwent genetic testing. Patients with possible inherited myopathy also underwent comprehensive genetic testing which included genes for myopathies and CMS. Patient demographics and clinical features were recorded and analyzed retrospectively. Electrodiagnostic features, autoantibodies, and molecular testing (where available) were also reported.
resultsFrom a single-center neuromuscular disease cohort of 639 adult patients, we identified seven (1.1%) patients with a clinical diagnosis of CMS. Four (57%) had onset of symptoms in adulthood, of whom two manifested in late adulthood. Six were initially misdiagnosed with seronegative myasthenia gravis or congenital myopathy. A genetic diagnosis was achieved in five (71.4%) patients with a median diagnostic delay of 17.8 years (range 1-38 years). Three patients from two families were identified to have COLQ-CMS, one patient with CHRNE-CMS, and one patient with CHRNA1-CMS. Two patients with COLQ-CMS had a multiphasic clinical course; one had no clear precipitants for her exacerbations. We reclassified two variants, COLQ(NM_005677.4): c.1352G > A p.Cys451Tyr and CHRNA1(NM_000079.4):c.823G > A p.Val275Met as likely pathogenic based on the American College of Medical Genetics criteria. We present an algorithm, based on our institution's experience, which may be helpful to facilitate the diagnosis of CMS in clinical practice.
conclusionsCMS is rare and challenging to diagnose in the adult neurology setting. We present a Southeast Asian cohort of seven adult patients with CMS and discuss their clinical and genotypic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.